Trials / Unknown
UnknownNCT04937972
SHR-1701 Combined With Fluzoparib in Lung Squamous Cell Carcinoma
SHR-1701 Combined With Fluzoparib as Maintenance Therapy for Advanced Lung Squamous Cell Carcinoma After Platium Based Chemo-immunotherapy
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 71 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the trial was to evaluate the efficacy and safety of SHR-1701 combined with fluzopar as a first-line treatment maintenance therapy for advanced lung squamous cell carcinoma. Patients with advanced or metastatic (stage IV) lung squamous cell carcinoma have not received systemic chemotherapy and have measurable lesions (RECIST 1.1) ECOG PS 0-1. The patient received SHR1701 +fluzoparib
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1701 Combined With Fluazopalil | SHR-1701 +fluzoparib |
Timeline
- Start date
- 2021-07-01
- Primary completion
- 2024-12-01
- Completion
- 2025-06-01
- First posted
- 2021-06-24
- Last updated
- 2023-12-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04937972. Inclusion in this directory is not an endorsement.